Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EBITDA (2021 - 2025)

Aligos Therapeutics' EBITDA history spans 5 years, with the latest figure at -$19.9 million for Q4 2025.

  • For Q4 2025, EBITDA rose 75.85% year-over-year to -$19.9 million; the TTM value through Dec 2025 reached -$24.2 million, up 81.59%, while the annual FY2025 figure was -$24.2 million, 81.59% up from the prior year.
  • EBITDA reached -$19.9 million in Q4 2025 per ALGS's latest filing, up from -$31.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $43.1 million in Q1 2025 to a low of -$82.3 million in Q4 2024.
  • Average EBITDA over 5 years is -$23.3 million, with a median of -$22.3 million recorded in 2022.
  • The largest YoY upside for EBITDA was 223.34% in 2025 against a maximum downside of 412.86% in 2025.
  • A 5-year view of EBITDA shows it stood at -$37.0 million in 2021, then skyrocketed by 41.52% to -$21.6 million in 2022, then decreased by 28.65% to -$27.8 million in 2023, then plummeted by 195.49% to -$82.3 million in 2024, then surged by 75.85% to -$19.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's EBITDA are -$19.9 million (Q4 2025), -$31.5 million (Q3 2025), and -$15.9 million (Q2 2025).